China Resources Double-Crane Pharmaceutical News

China Resources Double-Crane PharmaceuticalLtd's (SHSE:600062) Three-year Earnings Growth Trails the 22% YoY Shareholder Returns

Simply Wall StAug 7 00:22 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Subsidiary passes GMP compliance inspection.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its subsidiary, Zhejiang Xinsaike Pharmaceutical Co., Ltd., obtained the announcement of the GMP compliance inspection results from the Zhejiang Provincial Drug Administration. In this drug GMP compliance inspection, the API of moxidectin hydrochloride was the first drug GMP compliance inspection before listing. It is a new product added to the original production line, and the newly added investment in production equipment and facilities in the above workshop is 1.163 million yuan (unaudited). The API of tramadol hydrochloride was the first time to pass the GMP compliance inspection after the new production line was put into operation. The production equipment and facilities in the above workshop are

Gelonghui FinanceAug 6 04:56 ET

CR Double-Crane Pharmaceutical Unit Gets Drug Registration Certificate for Paliperidone Tablets

MT NewswiresJul 24 23:27 ET

China Resources Double-Crane Pharmaceutical (600062.SH): has completed the supporting construction of the synthesis biology from small-scale research to overall industrialization.

China Resources Double-Crane Pharmaceutical (600062.SH) stated on its interactive platform on July 23 that the company has completed the supporting construction of synthetic biology from small-scale research to overall industrialization, and has built a three-level industry system from research and development to pilot plant scale-up and then industrialization. The company has hired a chief scientist and established an R&D team. The small-scale platform has basically completed the construction of core capabilities such as molecular modification, high-throughput screening, strain verification, and enzyme engineering technology. In terms of pilot plant scale-up and industrialization, the focus is on promoting the construction of pilot fermentation workshops and building pilot conversion capabilities. Currently, six key projects of the synthetic biology technology platform are being promoted in an orderly manner, and actively participating in major national specialties.

Gelonghui FinanceJul 23 04:22 ET

China Resources Double-Crane Pharmaceutical Completes Phase 1 Trials for Semaglutide Injection for Diabetes Patients

MT NewswiresJul 22 04:24 ET

China resources double-crane pharmaceutical (600062.SH): Simcere Glucagon injection completed phase I clinical trial.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its Sumichrast's Felisyl Injection will be available on July 16, 2024...

Zhitong FinanceJul 19 05:14 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Some products have obtained supplementary drug application approval letters and chemical raw materials market application approval letters.

China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 9th that it has received the Drug Supplement Approval Notice for Aminophylline Injection from the National Medical Products Administration. Its wholly-owned subsidiary, Shuanghe Pharmaceutical (Shangqiu) Co., Ltd., received the Approval Notice for Active Pharmaceutical Ingredient Market Authorization Application from the NMPA.

Gelonghui FinanceJul 9 05:09 ET

Investors Aren't Buying China Resources Double-Crane Pharmaceutical Co.,Ltd.'s (SHSE:600062) Earnings

Simply Wall StJul 3 03:05 ET

Double-Crane Pharmaceutical Unit Gets China Nod for Influenza Drug

MT NewswiresJul 3 01:53 ET

China Resources Double-Crane Pharmaceutical (600062.SH): The pharmaceutical registration certificate for the injection of Parmiwe has been obtained.

China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 2nd that its wholly-owned subsidiary, Xi'an Jingxi Shuanghe Pharmaceuticals Co., Ltd., received the Drug Registration Certificate for parameve injection issued by the National Drug Administration. Parameve Injection is used to treat influenza A or B.

Gelonghui FinanceJul 2 05:20 ET

CR Double-Crane Pharmaceutical Registers Antibiotic, Ulcer Medications in China

MT NewswiresJun 28 01:10 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Some of its subsidiary's products have obtained pharmaceutical registration certificates.

On June 27, Gelunhui announced that its wholly-owned subsidiary, China Resources Double-Crane Pharmaceutical's Limin Pharmaceutical (Jinan) Co., Ltd., received a Drug Registration Certificate for Levofloxacin tablets from the National Medical Products Administration. Its another wholly-owned subsidiary, Double-Crane Pharmaceutical (Hainan) Co., Ltd., received a Drug Registration Certificate for Injection Roxatidine Acetate Hydrochloride from the National Medical Products Administration. Levofloxacin is a quinolone antibiotic used mainly to treat or prevent infections proven or highly suspected to be caused by sensitive bacteria. Roxatidine Acetate Hydrochloride for Injection is a histamine H2 receptor antagonist used for the treatment of upper.

Gelonghui FinanceJun 27 05:16 ET

CR Double-Crane Pharmaceutical Gets Certificate to Market Low-Calcium Dialysis Solution

MT NewswiresJun 13 23:38 ET

China Resources Double-Crane Pharmaceutical (600062.SH): Hemodialysis Low Calcium Peritoneal Dialysate (Lactate) Series Products Obtained Pharmaceutical Registration Certificate.

China Resources Double-Crane Pharmaceutical (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for low-calcium peritoneal dialysis solution (lactate-G1.5%), low-calcium peritoneal dialysis solution (lactate-G2.5%), and low-calcium peritoneal dialysis solution (lactate-G4.25%) issued by the State Drug Administration. The low-calcium peritoneal dialysis solution (lactate) series of products are mainly applicable to acute and chronic renal failure patients who need continuous non-bedridden peritoneal dialysis treatment due to ineffective non-dialysis treatment.

Gelonghui FinanceJun 13 05:22 ET

CR Double-Crane Pharmaceutical's Unit Gets Nod for Phloroglucinol Injection

MT NewswiresMay 27 04:07 ET

China Resources Shuanghe (600062.SH): resorcinol injection obtained drug registration certificate

China Resources Shuanghe (600062.SH) announced that China Resources Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd., a wholly-owned subsidiary of the company...

Zhitong FinanceMay 23 05:33 ET

CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Schizophrenia Drug

MT NewswiresMay 23 04:58 ET

Is China Resources Double-Crane PharmaceuticalLtd (SHSE:600062) A Risky Investment?

Simply Wall StMay 10 03:30 ET

CR Double-Crane Pharmaceutical's Unit Gets Nod for Lidocaine Hydrochloride Injection

MT NewswiresMay 8 00:14 ET

China Resources Shuanghe (600062.SH): Lidocaine hydrochloride injection obtained drug registration certificate

Gelonghui, May 7 | China Resources Shuanghe (600062.SH) announced that China Resources Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd. (“Shuanghe Limin”), a wholly-owned subsidiary of the company, has received lidocaine hydrochloride injection (“this drug”) and “Drug Registration Certificate” (certificate number: 2024S00640) issued by the State Drug Administration. Lidocaine hydrochloride injection is a local anesthetic and antiarrhythmic drug. It is mainly used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including mucosal anesthesia during thoracoscopy or abdominal surgery) and nerve conduction block. It can also be used in the room after acute myocardial infarction

Gelonghui FinanceMay 7 05:28 ET